Skip to main
COLL

Collegium Pharmaceutical (COLL) Stock Forecast & Price Target

Collegium Pharmaceutical (COLL) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Collegium Pharmaceutical is expected to have a strong performance over the next few years, as its product portfolio, which includes Jornay PM and Nucynta, has the potential for significant sales growth. The company is also expected to benefit from net profits from authorized generic versions of Nucynta in the future. Moreover, the company's strong projected top-line and expected increase in adjusted EBITDA for 2026, as well as potential BD activity, make it a worthwhile investment for long-term investors.

Bears say

Collegium Pharmaceutical is at risk due to potential generic erosion on their pain portfolio, limited future deal opportunities due to a recent balance sheet cleanup, and facing significant competition and headwinds with established products and generics which can impact their sales levels and reimbursements. Their recent update on Nucynta launch timing for both Nucynta ER and IR in 2026 also raises concerns about the sustainability of their financials.

Collegium Pharmaceutical (COLL) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Collegium Pharmaceutical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Collegium Pharmaceutical (COLL) Forecast

Analysts have given Collegium Pharmaceutical (COLL) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Collegium Pharmaceutical (COLL) has a Strong Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $55, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $55, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Collegium Pharmaceutical (COLL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.